Get the Stockscreener App
3.79
8.45%
-0.35
After Hours:
3.78
-0.01
-0.26%
Precigen Inc stock is traded at $3.79, with a volume of 5.37M.
It is down -8.45% in the last 24 hours and up +110.56% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$4.14
Open:
$4.1
24h Volume:
5.37M
Relative Volume:
0.72
Market Cap:
$1.13B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-9.7179
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
-13.07%
1M Performance:
+110.56%
6M Performance:
+112.92%
1Y Performance:
+282.09%
1-Day Range:
$3.77
$4.14
1-Week Range:
$3.77
$4.56
52-Week Range:
$0.6513
$5.225
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
3.79 | 1.22B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - MSN
4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next - PharmaVoice
EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS - Eastern Progress
Adage Capital Partners GP L.L.C. Boosts Holdings in Precigen, Inc. $PGEN - MarketBeat
Nuveen LLC Makes New Investment in Precigen, Inc. $PGEN - MarketBeat
Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism - Yahoo Finance
83,181 Shares in Precigen, Inc. $PGEN Purchased by MetLife Investment Management LLC - MarketBeat
Parkman Healthcare Partners LLC Takes Position in Precigen, Inc. $PGEN - MarketBeat
Recurrent Respiratory Papillomatosis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Precigen, Inovio Pharma - Barchart.com
Precigen Inc. Approaches Support With Recovery in SightJuly 2025 Trade Ideas & Weekly Top Gainers Alerts - beatles.ru
Precigen (NASDAQ:PGEN) Sets New 12-Month HighShould You Buy? - MarketBeat
Will Precigen Inc. stock go up in YEARGlobal Markets & Weekly High Return Opportunities - 뉴스영
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - The Motley Fool
Precigen (NASDAQ:PGEN) Trading 7.8% HigherStill a Buy? - MarketBeat
Precigen Inc. Rebounds From Oversold Zone — Now WhatWeekly Market Summary & Fast Gain Stock Tips - beatles.ru
Visual trend scoring systems applied to Precigen Inc.2025 Trading Recap & Consistent Growth Stock Picks - Newser
PGEN: JMP Securities Raises Price Target, Maintains Rating | PGE - GuruFocus
Should you wait for a breakout in Precigen Inc.July 2025 Intraday Action & Long-Term Safe Investment Plans - Newser
Is Precigen Inc. a top pick in the sectorRecession Risk & AI Powered Market Entry Ideas - خودرو بانک
Is Precigen Inc. stock good for income investorsJuly 2025 Update & Long-Term Safe Investment Ideas - خودرو بانک
What’s the profit margin of Precigen Inc.2025 Buyback Activity & Consistent Income Trade Ideas - خودرو بانک
Is Precigen Inc. a play on infrastructure spending2025 EndofYear Setup & Risk Managed Investment Entry Signals - خودرو بانک
Agee Nancy H, Precigen director, buys $69,000 in shares - Investing.com India
Agee Nancy H, Precigen director, buys $69,000 in shares By Investing.com - Investing.com Australia
Nancy Agee Increases Stake in Precigen Inc with Recent Purchase - GuruFocus
Live market analysis of Precigen Inc.Analyst Downgrade & Entry and Exit Point Strategies - Newser
Candlestick signals on Precigen Inc. stock todayShort Setup & Smart Swing Trading Alerts - Newser
Is Precigen Inc. stock risky to hold nowOptions Play & Weekly Setup with ROI Potential - خودرو بانک
Is Precigen Inc. stock bottoming outJuly 2025 Macro Moves & Reliable Price Breakout Signals - Newser
Will Precigen Inc. outperform the marketJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - Newser
Charles Schwab Investment Management Inc. Has $1.81 Million Stock Position in Precigen, Inc. $PGEN - MarketBeat
Is a relief rally coming for Precigen Inc. holdersBear Alert & Community Trade Idea Sharing - Newser
Reversal indicators forming on Precigen Inc. stockIPO Watch & Reliable Breakout Forecasts - Newser
Precigen, Inc. shares rise 1.05% premarket after securing a $125 million credit facility. - AInvest
Custom watchlist performance reports with Precigen Inc.July 2025 Review & Technical Pattern Alert System - Newser
How to recover losses in Precigen Inc. stockJuly 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Using data filters to optimize entry into Precigen Inc.July 2025 Weekly Recap & High Accuracy Investment Signals - Newser
Precigen secures $100 million in non-dilutive financing By Investing.com - Investing.com Canada
Precigen secures up to $125 million in senior secured loan financing By Investing.com - Investing.com Canada
Key metrics from Precigen Inc.’s quarterly dataTrade Exit Report & Safe Capital Growth Plans - Newser
Precigen Secures $125 Mln Credit Facility From Pharmakon To Advance PAPZIMEOS Commercialization - Nasdaq
Precigen Announces Up to $125 Million Non-Dilutive Financing - citybiz
Germantown's Precigen secures $125M loan to take first drug to market - The Business Journals
Precigen, Inc. announced that it expects to receive $125 million in funding - MarketScreener
Precigen announces up to $125M non-dilutive financing - MSN
What earnings revisions data tells us about Precigen Inc.Quarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Sector Update: Health Care - MarketScreener
BioPharma Credit to Invest $62.5 Million in US-based Precigen - MarketScreener
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):